TK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL157966	0.55	14/20
SCHEMBL315534	0.42	12/20
SCHEMBL913220	0.46	11/20
SCHEMBL913478	0.43	11/20
SCHEMBL913176	0.65	10/20
SCHEMBL445632	0.57	10/20
SCHEMBL445633	0.57	10/20
SCHEMBL914263	0.46	10/20
SCHEMBL913645	0.62	9/20
SCHEMBL768243	0.54	9/20
SCHEMBL591628	0.51	9/20
SCHEMBL992386	0.51	9/20
SCHEMBL992387	0.51	9/20
SCHEMBL593575	0.50	9/20
SCHEMBL592543	0.48	9/20
SCHEMBL593024	0.46	9/20
SCHEMBL1061655	0.45	9/20
SCHEMBL1061657	0.45	9/20
SCHEMBL260513	0.40	9/20
SCHEMBL912708	0.63	8/20

Clinical trials — most relevant to TK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression	PHASE2/PHASE3	NOT_YET_RECRUITING
Treatment of TK2 Deficiency With Thymidine and Deoxycytidine	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency	PHASE2	RECRUITING
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)	PHASE1/PHASE2	COMPLETED
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer	PHASE1/PHASE2	RECRUITING
Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine	PHASE2	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Comparison of Oxidants and Antioxidants in Breastmilk Under Different Anesthesia Protocols	nan	COMPLETED
A RETROspective Study of Patients With TK2d	nan	COMPLETED
Targeted Radiotherapy for Recurrent Prostate Cancer	nan	UNKNOWN
Natural History in Primary Mitochondrial Myopathies	nan	RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Clinical Study of Hydroxytyrosol (HT) in Mitochondrial Diseases	nan	COMPLETED
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING
TBI Multimodal Monitoring Study	nan	UNKNOWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib	nan	COMPLETED
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells	nan	RECRUITING
The Genetics of Diabetes in Southern California Chinese Americans	nan	WITHDRAWN
Digestive Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy	nan	UNKNOWN
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TK2 binder may also engage these)

Protein	Name	Similarity
Q9N0C5	—	1.000	Q9N0C5 →
Q9R088	—	0.997	Q9R088 →
Q9QX60	—	0.985	Q9QX60 →
Q16854	—	0.985	Q16854 →
Q8VDP3	—	0.976	Q8VDP3 →
Q91ZJ0	—	0.976	Q91ZJ0 →
FLAD1	FAD synthase	0.975	landscape →
Q9JJG9	—	0.974	Q9JJG9 →
D3ZBP4	—	0.974	D3ZBP4 →
P10937	—	0.974	P10937 →
Q80UN9	—	0.974	Q80UN9 →
Q9QYR9	—	0.973	Q9QYR9 →
Q8NC60	—	0.973	Q8NC60 →
Q99LC3	—	0.973	Q99LC3 →
O55171	—	0.973	O55171 →
Q8HY87	—	0.973	Q8HY87 →
Q5RJG7	—	0.973	Q5RJG7 →
P10938	—	0.973	P10938 →
P97930	—	0.973	P97930 →
PTGES2	Prostaglandin E synthase 2	0.973	landscape →
Q0MQB7	—	0.973	Q0MQB7 →
P48760	—	0.972	P48760 →
Q9GL72	—	0.972	Q9GL72 →
Q9H3H1	—	0.972	Q9H3H1 →
Q8TDZ2	—	0.972	Q8TDZ2 →
Q6P1R4	—	0.972	Q6P1R4 →
Q8CGS5	—	0.972	Q8CGS5 →
A7Z050	—	0.971	A7Z050 →
P70218	—	0.971	P70218 →
Q9BQ52	—	0.971	Q9BQ52 →